"Novartis’ 4CMenB Meningococcal Vaccine Wanes By Kindergarten Age In Clinical Trial" http://www.inquisitr.com/2041838/novartis-4cmenb-meningococcal-vaccine-wanes-by-kindergarten-age-in-clinical-trial/
This is the outcome of the two dose clinical strategy. The vaccine is doomed because of the crap assays, the antigen selection, and the clinical trial design. Why we paid for this I have no idea. Moncef did not do his homework, but does he ever?
MenC conjugate vaccine titres also wane after the infant dose series (as do most vaccines - infants can't hold their titres!) It does not mean that the vaccine will not be effective at reducing disease. Waning does not occur in adolescents, who are more likely to transmit the disease. In the 4 outbreaks where bexsero was recently used, there have been no cases in vaccinated individuals, despite continuing cases in neighbouring populations. Once people figure out that public health is waiting for a few kids get the disease before offering the vaccine, there will be a push to get it universally implemented. And you got bexsero for a bargain, so let stop the complaining, ok?
Infants do great with Hib, Dtap, PCV, HepB, MMR, Varicella, etc. The fact is that the GSK Men combo vaccine Mencevax is not very good. The NVS Menveo is way better for maintaining titres. Bexsero? Not so much.
The Pfizer/Wyeth Men B vaccine Trumemba does not wane by kindergarten age. It is however a three doses. I have heard that the UK will not renew the contract for Bexsero when it comes time.
I am going to have to call you bs on this. Trumemba has no studies in infants. Now go back under your bridge you troll.
